GentiBio could earn $1.9 billion under IBD deal with BMS
Boston, USA-based engineered regulatory T cells (Tregs) company GentiBio has entered into a collaboration with US pharma major Bristol Myers Squibb (NSE: BMY) to develop new engineered Treg therapies to re-establish immune tolerance and repair tissue in patients living with inflammatory bowel diseases (IBD).
The collaboration brings together GentiBio’s proprietary engineered Treg platform for generating scalable, stable, highly-selective, and durable Tregs with Bristol Myers’ leadership in cell therapies and immunology.
GentiBio launched two years ago, with $20 million seed funding from OrbiMed, Novartis Venture Fund and RA Capital Management. In August last year GentiBio also announced it has closed on a Series A financing generating immediate proceeds of $157 million.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze